bioAffinity Technologies Announces 1-for-15 Reverse Stock Split to Support Nasdaq Compliance
bioAffinity Technologies, Inc., a biotechnology company developing noninvasive technologies for the detection of early-stage cancer, has announced that it will implement a 1-for-15 reverse stock split of its common stock. The corporate action is scheduled to become effective before the opening of trading on the Nasdaq Capital Market on August 24, 2026.
Following the reverse stock split, the company’s common stock will continue to trade on Nasdaq under the existing ticker symbol BIAF, but on a post-split basis. The reverse split was previously approved by bioAffinity Technologies’ stockholders at the company’s annual meeting held on April 30, 2026.
The move is primarily intended to help the company regain compliance with Nasdaq’s minimum bid price requirement, an important listing standard for companies whose shares are traded on the exchange.
Details of the 1-for-15 Reverse Split
Under the terms of the reverse stock split, every 15 shares of bioAffinity Technologies’ issued and outstanding common stock will automatically be consolidated into one share. The transaction will reduce the total number of shares outstanding while proportionally increasing the market price per share, subject to normal market conditions.
The company expects to have approximately 592,373 shares of common stock issued and outstanding immediately after the reverse split becomes effective.
Shareholders will not need to take additional action to complete the consolidation of their shares. The reverse split will occur automatically at the effective time. Investors who would otherwise be entitled to receive a fractional share as a result of the transaction will instead receive a cash payment in lieu of the fractional share.
The company has appointed VStock Transfer LLC as the exchange agent responsible for administering the reverse stock split. Stockholders of record whose shares are held electronically in book-entry form will receive a transaction notice reflecting the number of shares held following the reverse split. Any applicable cash payment for fractional shares will also be handled according to the procedures of the relevant bank, broker or nominee.
New CUSIP Number for Common Stock
As part of the reverse stock split, bioAffinity Technologies’ common stock will receive a new CUSIP number, 09076W406. The CUSIP identifier is used to distinguish securities and facilitate processing and settlement within the financial markets.
While the common stock’s CUSIP number will change following the reverse split, the CUSIP number associated with the company’s publicly traded warrants will remain unchanged.
The company’s warrants and equity-based compensation arrangements will also be adjusted to reflect the reverse split.
Adjustments to Stock Options and Warrants
The reverse stock split will result in proportional changes to outstanding equity instruments issued by bioAffinity Technologies. Specifically, adjustments will be made to the per-share exercise prices and the number of shares underlying outstanding stock options.
Similar proportional adjustments will be made to the number of shares available for future awards under the company’s stock incentive plans. These adjustments are intended to preserve the economic relationship between the company’s equity awards and its common stock following the share consolidation.
Outstanding warrants to purchase shares of bioAffinity Technologies common stock will also be subject to proportional adjustments. Both the exercise prices and the number of shares underlying the warrants will be adjusted to account for the 1-for-15 reverse split.
Importantly, the company stated that the CUSIP number for its publicly traded warrants will not change as a result of the reverse stock split.
Focus on Nasdaq Listing Compliance
The principal reason for implementing the reverse stock split is to address Nasdaq’s minimum bid price requirement.
Stock exchanges such as Nasdaq establish minimum price standards that listed companies must satisfy to maintain their exchange listings. When a company’s share price falls below the required threshold for a specified period, it may receive a deficiency notice and be required to take corrective action.
A reverse stock split is one mechanism companies can use to increase the quoted price of their shares by reducing the number of shares outstanding. In bioAffinity Technologies’ case, the 1-for-15 consolidation is intended to raise the per-share trading price sufficiently to assist the company in meeting the applicable Nasdaq requirement.
The reverse split itself does not change the underlying proportionate ownership of shareholders immediately following the transaction, aside from the treatment of fractional shares. Instead, the number of shares owned by each investor will be reduced in accordance with the 1-for-15 ratio.
For example, an investor holding 150 shares before the reverse split would generally hold 10 shares after the transaction, before considering any fractional-share treatment.
Continued Development of Cancer Detection Technologies
The corporate action comes as bioAffinity Technologies continues to focus on its biotechnology platform and its efforts to develop noninvasive diagnostic technologies for cancer detection.
The company is focused on addressing the need for improved approaches to identifying cancer at earlier stages, when treatment may be more effective. Its work is centered on technologies designed to support noninvasive detection and characterization of disease.
While the reverse stock split is primarily a corporate and financial action intended to support Nasdaq listing compliance, the company’s broader business strategy remains focused on advancing its diagnostic technology programs and developing solutions for unmet needs in cancer detection.
Shareholder Impact and Implementation
The reverse stock split will be implemented automatically, meaning shareholders do not need to exchange existing stock certificates or take separate action to participate in the transaction.
Investors holding shares through brokerage accounts, banks or other nominees may see the adjusted share balance reflected in their accounts following implementation. The timing of account updates may vary depending on the procedures used by individual financial institutions.
Any shareholder who becomes entitled to a fractional share following the reverse split will receive cash instead of the fractional interest. The company expects its transfer agent and relevant financial intermediaries to handle these adjustments as part of the standard post-split process.
Additional information about the transaction is available in bioAffinity Technologies’ definitive proxy statement filed with the U.S. Securities and Exchange Commission (SEC).
The 1-for-15 reverse stock split represents a significant capital structure adjustment for bioAffinity Technologies as the company seeks to address Nasdaq’s minimum bid price requirement. Beginning August 24, 2026, investors will see the company’s common stock trading on a post-split basis under the BIAF ticker.
With approximately 592,373 common shares expected to remain outstanding following the transaction, the reverse split will substantially reduce the number of shares in circulation while proportionally adjusting applicable stock options, incentive awards and warrants.
For bioAffinity Technologies, maintaining compliance with Nasdaq listing standards provides an important foundation as the company continues pursuing its biotechnology programs. The company remains focused on its goal of developing noninvasive cancer detection technologies, while the reverse stock split is designed to address an immediate corporate and market-listing requirement.
About bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW)
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.